Among people with ANCA-associated vasculitis (AAV), those with central diabetes insipidus are more frequently diagnosed with granulomatosis with polyangiitis (GPA), a type of AAV, according to a study in China. Central diabetes insipidus, or CDI, is a rare disease characterized by excessive thirst and excessive urine. Patients with…
Central diabetes insipidus more common in AAV patients with GPA
Researchers in Korea have identified a new index that can predict all-cause mortality in non-obese people with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The index accounts for blood levels of fatty molecules called triglycerides and blood sugar, as well as body mass index (BMI, a ratio of height and…
A combination of two standardized scores of kidney damage can accurately predict the prognosis of renal disease in people with ANCA-associated vasculitis (AAV), a study indicates. This composite measure — the renal risk score (RRS) and the renal vascular lesions (RVL) score — “may serve as a new predictor…
Immunosuppressants may help prevent subglottic stenosis — a condition wherein part of the windpipe becomes tight — from returning in people with a type of ANCA-related vasculitis called granulomatosis with polyangiitis (GPA), a small Italian study suggests. The study, “Role of systemic immunosuppression on subglottic stenosis in granulomatosis…
A blood marker, called C-reactive protein to albumin ratio (CAR), may predict and help monitor disease activity in people with ANCA-associated vasculitis (AAV), according to a small study in Turkey. This is important in clinical practice because “close monitoring, early recognition, and timely treatment of disease activity may limit…
Two types of self-reactive antibodies, called anti-HMGB1 and anti-moesin antibodies, are present at significantly higher levels in the blood of ANCA-associated vasculitis (AAV) patients relative to healthy people and those with other autoimmune diseases, a study shows. The levels of these antibodies are also linked to how AAV manifested…
About 1 in 10 people with ANCA-associated vasculitis (AAV) failed to achieve complete remission at three months after starting induction treatment with rituximab, according to a small study in France. Poor responders were more likely to have symptoms in a specific area of the body — a localized form…
A new statistical model that considers age, disease type, patterns of organ involvement, and lab findings may help predict long-term survival in ANCA-associated vasculitis (AAV) better than available prognostic systems, a study suggests. The study “Development and internal validation of a model to predict long-term survival of ANCA…
Smoking at any time during one’s lifetime leads to more advanced disease and worse prognosis for people with ANCA-associated vasculitis (AAV), according to a 32-year study in Poland. Specifically, current or past smoking is linked to higher disease activity at diagnosis, and a greater need for kidney replacement and…
Despite high response rates to treatment strategies to reduce ear, nose, and throat involvement in ANCA-associated vasculitis (AAV), relapses are common, a review study reports. The study, “Systemic and Local Medical or Surgical Therapies for Ear, Nose and/or Throat Manifestations in ANCA-Associated Vasculitis: A Systematic Literature Review,” was…
Recent Posts
- New analysis identifies phase-specific relapse risks in AAV treatment
- Sharing with others about vasculitis can strengthen connections
- New nanoparticle approach targets kidney damage in vasculitis
- Study points to 2 biomarkers for AAV disease activity, relapse
- Monitoring our kidney health is crucial with ANCA vasculitis